A reduction in hip fracture incidence following population screening might reflect the effectiveness of antiosteoporosis therapy, behaviour change to reduce falls, or both. This post hoc analysis demonstrates that identifying high hip fracture risk by FRAX was not associated with any alteration in falls risk. Introduction To investigate whether effectiveness of an osteoporosis screening programme to reduce hip fractures was mediated by modification of falls risk in the screening arm. Methods The SCOOP study recruited 12,483 women aged 70-85 years, individually randomised to a control (n = 6250) or screening (n = 6233) arm; in the latter, osteoporosis treatment was recommended to women at high risk of hip fracture, while the control arm received usual care. Falls were captured by self-reported questionnaire. We determined the influence of baseline risk factors on future falls, and then examined for differences in falls risk between the randomisation groups, particularly in those at high fracture risk. Results Women sustaining one or more falls were slightly older at baseline than those remaining falls free during follow-up (mean difference 0.70 years, 95%CI 0.55-0.85, p < 0.001). A higher FRAX 10-year probability of hip fracture was associated with increased likelihood of falling, with fall risk increasing by 1-2% for every 1% increase in hip fracture probability. However, falls risk factors were well balanced between the study arms and, importantly, there was no evidence of a difference in falls occurrence. In particular, there was no evidence of interaction (p = 0.18) between baseline FRAX hip fracture probabilities and falls risk in the two arms, consistent with no impact of screening on falls in women informed to be at high risk of hip fracture. Conclusion Effectiveness of screening for high FRAX hip fracture probability to reduce hip fracture risk was not mediated by a reduction in falls.
Introduction
In 2010, in the EU, there were 610,000 hip fractures with their management alone accounting for €25bn of expenditure [1] . Of many factors that influence the risk of hip fracture, age-related reductions in bone mass and increased likelihood of falling are long recognised to be important contributors [2] . While assessment of falls risk and appropriate interventions aimed at reducing falls risk has been shown to be effective [3] , at least in the short term, their impact on the risk of hip fracture is less certain. For example, in a recent review undertaken for the US Preventive Services Task Force, multifactorial interventions or single exercise-based interventions were found to reduce falls risk, but the impact on fractures was not significant [4] . In contrast, several randomised, placebo-controlled trials have shown that treatments directed at preventing bone loss and/or improving bone mass can reduce the incidence of hip fracture by 30-45% [5] [6] [7] .
Recently, the UK-based SCOOP study investigated whether community-based screening, using a FRAX assessment of 10-year hip fracture probability, could reduce the incidence of fractures by targeting osteoporosis treatment to women at high risk of hip fracture [8] . This large study with 5 years of followup found that the screening programme led to a 28% reduction in hip fractures. A subsequent analysis confirmed that the risk reduction was predominantly observed in those deemed to be at high risk of fractures [8, 9] , suggesting the effect was mediated by appropriately targeted osteoporosis medication. An alternative hypothesis might be that screening itself, and/or the knowledge of being at high risk, coupled with the patient's perception of linkage between falls and fractures, could have altered behaviour related to falls risk. Evidence exists that screening can encourage those screened to improve their health behaviour [10] , and that screening participants are more likely to follow health-related feedback and alter their lifestyle than those who do not participate [11, 12] . In contrast, screening can have a 'certificate of health' effect whereby a negative screening result gives patients reassurance which makes them more resistant to health recommendations in the future as they believe that their current lifestyle is adequate and have a lower perceived threat of disease [10, 11, 13] .
Given these potential impacts of screening on lifestyle factors, there is uncertainty as to whether screening for osteoporosis might influence falls occurrence or behaviour. This post hoc analysis of the SCOOP trial aimed to answer this by identifying risk factors for falling, comparing their distribution in the screening and control arms and, finally determining whether falls were reduced in the screening arm, particularly in women informed to be at higher risk of hip fracture and targeted for anti-osteoporosis medications.
Methods
The SCOOP study, a 5-year randomised controlled trial of the impact of screening for high hip fracture risk on fracture incidence, has been described in detail elsewhere [8, 14] . Briefly, it recruited 12,483 women aged between 70 and 85 years, untreated for osteoporosis, from 100 GP practices in 7 regions across England.
Baseline data and randomisation
At study entry, clinical risk factors were collected directly from participants by postal questionnaire to assess fracture probability by FRAX. Variables included age, height and weight (to calculate BMI), as well as prior fracture (since the age of 50 years), parental hip fracture, glucocorticoid use, rheumatoid arthritis, smoking, and alcohol exposure. Selfreported causes of secondary osteoporosis, including insulindependent diabetes, Crohn's disease, thyroid overactivity, early menopause, organ transplantation, and poor mobility, were collected, as well as the number of self-reported falls in the previous 12 months [14] . Participants were then randomised into the two arms of the study, the screening arm or 'usual care' control arm.
Screening and control arms
In the screening arm, the FRAX tool was used to calculate participants' 10-year probability of hip fracture, with those deemed at moderate to high risk of hip fracture invited for a dual-energy x-ray absorptiometry (DXA) measurement of femoral neck bone mineral density (BMD); the 10-year hip fracture probability was then recalculated with inclusion of BMD. The final risk category (low or high) was communicated to the participant and family doctor with those at high risk advised to discuss treatment options. Whether at low or high risk, the GP was also asked to advise about the need to increase exposure to weight-bearing exercise, to stop smoking, and to decrease alcohol intake, where appropriate. In the control arm, apart from communications to the GP and participant about their inclusion in the study, they received usual care from their GP and did not receive information about fracture risk.
Prior falls and incident falls
Falls in the previous 12 months were captured at study entry and self-reports of subsequent falls were captured by postal questionnaire at 6, 12, 24, 36, 48, and 60 months postrandomisation, where patients reported falls occurring since the previous questionnaire completion. Prior or subsequent reported falls were not validated from other independent sources during follow-up. A fall was defined as a sudden, unintentional coming to rest on the ground, floor, or other lower level [15] .
Statistical analysis
Differences in baseline characteristics, including clinical risks for FRAX calculation, between those women with or without a fall in the year prior to entry were compared using relevant descriptive statistics.
The proportion of women remaining fall-free was estimated with the Kaplan-Meier method [16] . Cox regression was used to examine the relationships between incident falls and baseline risk factors as well as the assigned study arm, with and without adjustment for predictors of falls. Any participant self-reporting one or more falls during follow-up was classified as a faller. Sensitivity analyses using faller definitions of those experiencing at least 5 falls (i.e. on average 1 or more falls per year during the 5 years of the study) and those experiencing at least 10 falls (i.e. on average 2 or more falls per year during the 5 years of the study) were also conducted.
An extension of Poisson regression model was used to study the relationship between age, the time since baseline, study arm (screening or usual care), and FRAX 10-year probability of hip fracture on the one hand and on the other hand, the time to first fall for base case, and time to 5th or 10th fall for sensitivity analyses. As BMD measurements were not undertaken in all participants, the baseline 10-year FRAX probabilities, without the inclusion of BMD, were utilised for these analyses. The variable "10-year probability screening" tested for an interaction between screening effectiveness and baseline 10-year probability, handled as a continuous variable. No reduction in falls risk and a lack of interaction, with a flat relationship across the range of baseline risk, would suggest that screening had no impact on falls risk to mediate the observed reduction in hip fractures. A similar approach was used to investigate an interaction between hip fracture probability and reduced fracture risk in the screening arm compared with the control arm [9] .
All analyses were conducted on an intention-to-treat basis with participants analysed according to the group to which they were randomised, irrespective of whether screening was completed. Hazard ratios (HR) for screening effect and 95% confidence intervals (95% CI) were computed for risk of falls as a continuous variable. For presentation, hazard ratios are shown at the 10th, 25th, 50th, 75th, and 90th percentile of fracture probability.
Results

Baseline characteristics
The baseline characteristics of the participants in each study arm are shown in Table 1 . There were no appreciable differences between the two arms of the study; importantly, the prevalence of falls in the year prior to study entry was very similar in both arms whether this was analysed as any reported fall or a history of 2 or more falls (i.e. multiple previous falls) ( Table 1) . Within the screening arm, the prevalence of multiple previous falls was slightly but not significantly higher (14.9%) in those identified at high future risk of hip fracture by FRAX probability than in the rest of the screening group (13.1%, p = 0.16).
Women with a history of one or more falls in the previous year were slightly older, with a higher mean BMI, and higher prevalence of FRAX risk factors apart from smoking ( Table 2 ).
Incident falls
During the follow-up period providing 59,401 person-years of observation (mean 4.75 years per participant), there were 24,540 incident falls reported, with 6760 (54.2%) of women reporting at least one fall. The proportion of women sustaining a new fall was similar in the control arm (3332 of 6250, 53.3%) and the screening arm (3428 of 6233, 55.0%). Within those reporting incident falls, the total number of falls reported in any individual ranged from 1 to 314, with the majority (4743, 70.2%) reporting 3 falls or fewer (Table 3) .
Those women who sustained one or more incident falls were slightly older at baseline (mean 75.8 years) than those remaining fall-free during follow-up (mean 75.1 years) (mean difference 0.70 years, 95% CI 0.55-0.85, p < 0.001). A number of other baseline characteristics were associated with the incidence of subsequent falls, largely independent of the number of incident falls used to classify an individual as a faller or not (Table 4 ). Thus, a higher BMI, a history of prior fracture, glucocorticoid use, secondary osteoporosis, and fall or the number of falls in the year prior to entry were consistently associated with an increased risk of falling across the different classifications of fallers. In addition, a higher FRAX 10-year probability of hip fracture was also consistently associated with higher subsequent risk of falling with fall risk increasing by 1-2% for every 1% increase in hip fracture probability (Table 4 ). Importantly, there was no evidence that assignment to the screening arm had an impact on the future incidence of falls (Table 4 and Fig. 1 ). Fall-free survival, whether this was defined as free from any fall (Fig. 1a) or, at the other extreme, free from at least 10 falls ( Fig. 1b) was very similar in the screening and control arms.
Interaction between hip fracture probability, screening, and falls risk
The relationship between the hazard ratio for any incident fall in the screening arm compared with that in the control arm, across the range of baseline FRAX 10-year hip fracture probabilities, is shown in Fig. 2 . There was no evidence of an interaction (p = 0.18) with no difference in falls risk between the screening and control arms across the full range of baseline hip fracture probability. The results were also similar by number of incident falls (Online resource 1). Confidence intervals for the hazard ratio crossed unity at all probabilities for the various fall outcomes, with no evidence of an interaction.
Discussion
This analysis was designed to explore whether the reduction in hip fractures seen in the SCOOP study might have been mediated by a change in behaviour and decreased falls risk in the screening arm, particularly in those identified at high risk.
The results show no impact of screening on the incidence of falls, however defined, and this was true across the full range of baseline fracture risk. This result complements a similar analysis which showed an interaction between screening and the reduction in hip fractures in those at higher risk in SCOOP.
Together, these analyses are consistent with the effect of targeting of osteoporosis medications to such individuals [9] , rather than a reduction in the frequency of falls. Our analysis identified a number of clinical risk factors associated with a future risk of falling, consistent with existing literature [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , including a history of one or more falls in the previous year, a prior fracture, and self-reported poor mobility. All three factors also showed a strong relationship with the occurrence of multiple falls. Interestingly, we found that FRAX hip fracture probability, calculated without input of BMD, was also predictive of future falls across all definitions of future fallers. In a study of elderly men included in the MrOS Sweden cohort, the risk of incident falls also increased with increasing FRAX probabilities at baseline [27] , and our analysis suggests that this finding also applies to women.
That the reduction in hip fractures seen in SCOOP is not mediated by a change in behaviours impacting on falls risk is an important finding. While there is evidence from previous studies in other disease areas that screening can exert positive or negative influences on health behaviour [10] [11] [12] [13] , it is clear that screening for high fracture risk had no impact on falls occurrence in SCOOP. That falls risk is an important contributor to incident hip and non-vertebral fractures are both logical and demonstrable [28] [29] [30] [31] [32] ; however, the SCOOP study demonstrates that the incidence of hip fracture can be reduced by treatments that target osteoporosis rather than falls risk. These data are in keeping with a large body of evidence from randomised, placebo-controlled clinical trials of predominantly anti-resorptive treatments in osteoporosis [6, 7, 33, 34] . Of note, a similar, if smaller, reduction in hip fracture has also been reported in the ROSE screening study in Denmark using a slightly different FRAX-based strategy [35] , suggesting that FRAX-based targeting of osteoporosis treatments might play a significant role in decreasing the burden of hip fractures. That the efficacy of intervention is mediated predominantly by changes in BMD is supported by the comparative effects of the intervention on hip fracture and osteoporotic fracture. For the prediction of hip fracture, risk decreases 2.6-fold for each standard deviation increase in femoral neck BMD, whereas the decrease in risk for any osteoporotic fracture is in the order of 1.5-fold [36] . Given that the hip fracture rate decreased by 28%, the expected effect on osteoporotic fractures would be a hazard ratio of 0.87; this hazard ratio lies within the 95% confidence intervals of the effect reported in SCOOP for osteoporotic fractures (0·85-1·03) [8] . In contrast, uncertainty remains about the effectiveness and cost-effectiveness of falls prevention strategies to reduce hip fracture risk, compared, for example, with the targeted use of generic pharmacological interventions such as those used in SCOOP [4, [37] [38] [39] . This does not mean that falls prevention measures should not be included in patient management, but it does raise serious Numbers represent the hazard ratio (HR) and 95% CI for the presence of the factor, other than for continuous variables where the HR relates to a unit increase in the variable, adjusted for age and time since baseline. Numbers in italics represent HRs with a CI that excludes the null Fig. 1 Fall-free survival estimated by Kaplan-Meier analysis for the outcomes of any fall (a) (i.e. one or more) and multiple falls (b) defined as 10 falls or more. There were no statistically significant differences between screening and control groups. NB Note differences in the yaxis scales between the figures questions about the wisdom of calls for anti-osteoporosis medications for the prevention of hip fractures to be abandoned in favour of falls prevention focused strategies [40, 41] .
Our study has a number of strengths and limitations. One of the strengths of this analysis was that it was undertaken within the context of a well-conducted, large, randomised, controlled clinical trial with a high incidence of the outcome of interest (falls). Falls were not the primary outcome of SCOOP, however, and past falls and incident falls were captured by unverified self-report only, most commonly at 1-year intervals by questionnaire. Self-recall is associated with lower sensitivity (under-reporting of falls) but a high specificity [42] . This recall can be influenced in studies of interventions that target falls prevention, but this was not the case in SCOOP and there is no reason to believe that any recall bias was unequally distributed between the screening and control arms. Additionally, the findings were robust across a series of definitions of fallers. Furthermore, the finding of well-established relationships between known risk factors and incident falls, however categorised, not only gives credence to the reporting of falls but also further validates the accuracy of the observed lack of impact of screening on falls risk.
Conclusion
The SCOOP study, which targeted osteoporosis treatment to women at high risk of hip fracture, resulted in a lower incidence of hip fracture. The present analysis demonstrates that this reduction in hip fractures was not mediated by a reduction in falls risk. The additional benefits, if any, of combining effective osteoporosis treatments with approaches aimed at addressing falls risk should ideally be determined from welldesigned clinical trials to inform best clinical practice. 
